N4 PHARMA PLC — Board/Management Information 2017

Jul 11, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 7072K

N4 Pharma PLC

11 July 2017

11 July 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Change in Director Details

In accordance with Rule 17 and paragraph (g) of Schedule Two of the AIM Rules for Companies, the Company announces that it was on 10 July 2017 notified by Paul Titley, an Executive Director of the Company, that Critical Pharmaceuticals Limited ("Critical"), a company of which he is a Non-Executive Director, has been placed into creditors' voluntary liquidation. Mr Titley's authority as a director of Critical ceased on appointment of the liquidator.

Enquiries:

N4 Pharma CEO, Nigel Theobald	Via Alma PR
Stockdale Securities Tom Griffiths	Tel: +44(0)207 601 6100
Beaufort Securities Elliot Hance	Tel: +44(0)207 382 8300
Alma PR Josh Royston Robyn Fisher	Tel: +44(0)778 090 1979 Tel: +44(0)754 070 6191

About N4 Pharma

N4 Pharma  is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance. Its shares were admitted to trading on AIM on 3 May 2017.

N4 Pharma's reformulation work falls under two divisions:

• generic, already commercialised, drugs; and

• delivery of novel and existing vaccines.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra, where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAEANXFFANXEEF